Objective Advanced glycation end products (AGEs) are involved in diabetes complications. We aimed to investigate whether the accumulation of AGEs measured by skin autofluorescence (sAF) was associated with signs of diabetic peripheral neuropathy and to sensitivity, pain, motor and autonomic function 4 years later in patients with type 1 diabetes.
Introduction
Diabetic peripheral neuropathy (DPN) affects approximately 50% of diabetic patients [1] . DPN occurs insidiously with a length-dependent pattern and starts distally, with symptoms such as neuropathic pain, foot reduced sensitivity and reflex [2, 3] . Advanced glycation end products (AGE) play an important role in the pathophysiology of diabetic complications. Exposure to chronic hyperglycemia and oxidative stress leads to the formation of AGE; their accumulation contributes to 'metabolic memory', to the functional modification of tissues and cells [4, 5] and to the development of DPN [6] . In the Diabetes Control and Complications Trial study on type 1 diabetes, the AGE concentrations were higher in the skin biopsies of patients with neuropathy [7] .
The accumulation of AGE in the skin can be assessed non-invasively based on the fluorescence of some AGE, such as pentosidine [8] . We recently showed that the skin autofluorescence (sAF) of AGE reflects the glycemic exposure of the preceding 10 years and, thus, could be a marker of metabolic memory in elderly subjects [9] . However, the relationship between the sAF and later DPN has not been explored in type 1 diabetes. We hypothesized that non-invasive measurement of AGE by sAF could have a value for the occurrence of signs and symptoms of neuropathy.
Thus, we aimed to analyse the relationship between sAF and signs of DPN 4 years later in patients with type 1 diabetes. We also analysed the association of sAF with four neurological tests that assessed pain, sensitivity, motor and autonomic function 4 years later.
Methods

Study population (Flow chart: Figure 1)
The study was conducted in a sample of adults with type 1 diabetes (n = 240) who were followed at the NutritionDiabetology unit of the University Hospital Haut-Levêque (Bordeaux, France) [10] . At baseline in 2009, 240 patients with type 1 diabetes and 18 years and older were recruited. The sAF was measured, and the general and clinical characteristics were recorded. At follow-up, 4 years after the baseline examination, signs of DPN were recorded, and four neurological tests that assessed each domain of nerve function involved in DPN were conducted.
Among the 240 patients who were included at baseline, 221 patients were seen 4 years later in 2013, 13 were lost to follow-up and 6 died. After the exclusion of 15 participants who were not screened for DPN and 18 participants who had missing data for anthropometric measurement and tobacco consumption, 188 participants were available for the analysis of the association between sAF and signs of DPN 4 years later. For the analysis of the association of sAF with neurological test results, 132 participants had  evaluations with respect to vibration perception threshold  (VPT), neuropathic pain and muscle strength, and 100  participants had measurements taken of their electrochemical skin conductance (ESC). At baseline, the data collected included the age, gender, smoking, height, weight and body mass index (BMI, body weight/height 2 [kg/m 2 ]), hypertension, use of an insulin pump, duration of diabetes (years), HbA 1c , estimated glomerular filtration rate (eGFR, estimated with the CKD-EPI formula) and urinary albumin excretion rate (AER).
Standard protocol approvals, registrations and patient consents
Written informed consent was obtained for all participants.
Skin autofluorescence measurement
The accumulation of AGE in skin was measured at baseline by the AGE reader (DiagnOptics BV, Groningen, the Netherlands) and expressed in arbitrary units (AU) [8] . The measurement was performed at a normal skin site without scars, lichenification or other abnormalities. The Fitzpatrick phototypes V and VI were not evaluated because of their skin pigmentation, which had ultraviolet reflectance of <10% [11] .
Assessment of neuropathy
At the 4-year follow-up examination, signs of DPN were defined by the occurrence of neuropathic pain and/or feet sensory loss, foot ulceration or neuropathic osteoarthropathy (in one case) [12] .
Neurological tests
The VPT for the assessment of sensitive function in peripheral neuropathy was measured by neurothesiometry (Arnold Horwell, London, U.K.) at the two halluces. The neuroethesiometer was applied with a progressive increase in voltage until the patient perceived the vibration. The VPT was expressed in volts (V) and calculated as the mean of the right and left halluces [13] .
The 'Douleur Neuropathique en 4 Questions' (DN4) is a validated screening questionnaire for neuropathic pain with a score between 0 and 10 that indicates the number of signs of painful neuropathy [14] . The DN4 evaluates seven items that are assessed by interview and three items that are assessed by physical examination. Each item is scored as 1 if a positive response is given and 0 if a negative response is given. The interview consisted of questions about the pain characteristics (burning, painful, cold, electric shocks, tingling, pins and needles sensation, numbness and itchiness).The physical examination tested sensitivity to touch, pinprick and brush. For the present study, we considered a score of ≥1 to be clinically significant.
Muscular strength was assessed by dynamometry. We performed three consecutive measurements of the handgrip strength in the dominant hand with a calibrated dynamometer (Takei Scientific Instruments, Tokyo, Japan). The mean of the three values was recorded [15] .
The autonomic nerve function was assessed by Sudoscan, which is a non-invasive test that is designed to evaluate sweat gland function based on ESC. The ESC is generated by a direct current stimulus (≤4 V) applied to the electrodes and sodium chloride of sweat. The ESC is expressed in microSiemens (μS) and is the ratio of the current generated in proportion to the chloride involved in electrochemical reaction with electrodes and the direct current stimulus [13, 16] . For the current study, we used the mean ESC of the feet.
Statistical analysis
In the univariate analysis, participants with and without signs of neuropathy were compared according to their characteristics at baseline and their results in the neurological tests; Student test was used for continuous variables, and the χ2 test or Fisher test was used for the categorical variables. The VPT was log-transformed because the distribution was skewed. To analyse the association between the sAF and DPN at 4 years, we considered the sAF to be a continuous variable. However, for neurological tests, the relation between the sAF and all of the neurological tests except for the muscle strength was not linear. Thus, we categorized the sAF into quartiles: sAF ≤ 1.75 AU, 1.75 < sAF ≤ 2.00, 2.00 < sAF ≤ 2.40 and sAF > 2.40. The results of the neurological test were compared according to the sAF quartiles. First, we used a global test of ANOVA to compare the quantitative results of the neurological tests and a Fisher test for the percentage of subjects with a score of ≥1 for the DN4 questionnaire. Then, to compare the highest quartile (sAF > 2.40) to the three others, a Student test and χ2 test were used.
In the multivariate analysis, the baseline characteristics that were associated with both the presence of signs of neuropathy at follow-up and with sAF at p < 0.25 were introduced into the models; the HbA 1c was forced. For each analysis, we performed a first model (Model 1) that included the sAF, age and sex. In a second model (Model 2), the height, BMI, smoking status, hypertension, HbA 1c and diabetes duration were added. Finally, in a third model (Model 3), the eGFR and AER were added. Logistic regression models were used to determine the association between the sAF and signs of DPN; the sAF was transformed into the Z-score, and the odds ratios were expressed as +1 SD change in the sAF. For the association between sAF and the results of neurological tests, the highest sAF quartile was compared with the three other quartiles. Logistic regression models were used for the analysis of the DN4 score (dichotomous variable, DN4 score ≥1). Linear regression models were used for the three other neurological tests (continuous variables). For the analysis of the relationship of sAF with muscular strength, an interaction term between sAF and sex was introduced in the model; if it was significant the analysis was realized separately in men and women.
All analyses were performed with SAS Statistical Package release 9.3 (SAS Institute, Cary, NC) and a p-value of less than 0.05 was considered significant.
Results
Baseline characteristics and neuropathy at the 4-year follow-up
The study sample included 188 patients; 43.1% were women with an average age of 51.4 (SD = 15.8) years, and the mean diabetes duration was 22.2 (SD = 13.3) years. Four years after the measurement of sAF, 26 (13.8%) patients had signs of DPN; compared with patients without DPN, these patients were older, had longer diabetes duration, more hypertension, lower eGFR, higher AER and higher sAF at baseline (Table 1) .
In the multivariate analysis, the association between zAF and DPN is still significant, with an increase in the odds ratio that is related to the Z-score sAF even after adjustment for vascular risk factors in model 2 and renal function in the model 3. In the fully adjusted model, the sAF, age, height, BMI, diabetes duration and HbA 1c were independently associated with DPN. Each SD change in sAF was associated with a 2.68 greater likelihood of having a sign of DPN at the 4-year follow-up (Table 2) .
Neurological tests at the 4-year follow-up
The majority of neurological tests displayed a normal value of the function that was measured: in the sample of 132 patients, the mean VPT was 11.3 (SD = 10.2) V, 38.6% had a DN4 score ≥1, the mean muscle strength was 31.2 (SD = 12.2) kg and the mean feet ESC was 74.0 (SD = 12.6) μS in the sample of 100 patients.
Compared with the other patients, the patients with signs of neuropathy had higher VPT (25.9 vs 9.6 V, p < 0.0001 after log transformation), lower muscle 
sAF and neurological tests
The performances on the four tests according to the quartiles of sAF at the baseline are shown in Table 4 .
Compared with the other quartiles, the performances were significantly worse in the highest quartile for all of the tests. Between the lower and the highest quartile of sAF, there was an increase of approximately 10 V of VPT, an increase of 25% in individuals with a DN4 score of ≥1, a loss of 10 kg in hand strength and a decrease of 10 μS in the feet ESC. After multivariate adjustment, the highest quartile of sAF was associated with poorer neurological test performances in three out of the four tests. A sAF of >2.4 was associated with a higher VPT (logarithm β = 0.36, 95% 
Discussion
The deposit of AGE in the peripheral nerves of patients with diabetes is a well-known mechanism for neural lesions [6] . The development of sAF provides a simple, quick, non-invasive mode of measurement but it remains to be established whether this measurement can help in the early diagnosis of DPN. In our patients with type 1 diabetes, a high sAF was associated with a higher risk of signs of neuropathy 4 years later, and the highest quartile of sAF was associated with the worst neurological test results (VPT, DN4 score, muscle strength and feet ESC) 4 years later.
Cross-sectional studies have already reported a relation between the sAF and microangiopathic complications such as retinopathy and nephropathy in type 1 diabetes [10] as well as a relation with neuropathy defined by the presence of two or more signs or symptoms [17] . This relation was also found using another device that measures skin intrinsic fluorescence [18, 19] . In the pioneer work of Meerwaldt et al., including 13 patients with type 1 diabetes and 34 with type 2 diabetes, the relation between sAF and nerve conduction velocities was present even without the clinical manifestations of neuropathy, which suggests that altered sAF could precede them [20] . However, longitudinal studies provide stronger arguments for a causal relationship between sAF, as a marker of AGE accumulation and metabolic memory, and DPN, where high levels of tissue [21] or circulating [22] AGE are reported. To our knowledge, only one longitudinal study has been published, which involved 881 patients with type 2 diabetes, 7.5% of whom developed DPN as defined by diminished sensibility with 5.07/10 g monofilament during the three years following their sAF measurement [23] ; the relation between sAF and the later development of neuropathy was significant after adjustment to the diabetes duration in this cohort, which is in accord with our results on type 1 diabetes. Furthermore, because DPN has heterogeneous manifestations that involve different nervous functions [2] , we systematically assessed the sensitivity, pain, motor and autonomic function. To our knowledge, there is no evaluation of the link between sAF and results from this combination of neurological tests.
In DPN, large myelinated fibre lesions contribute to the loss of foot sensitivity [2] . The loss of foot sensitivity can be measured by VPT which predicts foot ulceration [24, 25] . For this measurement, the neurothesiometer has the advantage of providing a quantitative value to estimate the large nerve lesion severity. Consistent with our findings, cross-sectional studies found a relationship between the long-term glycemic control, reflected by the mean HbA 1c over more than 9 years, and the VPT or large fibre conduction [26] . Additionally, correlations were reported between the skin intrinsic fluorescence or the sAF and VPT [18] [19] [20] . In the present study, a difference of 10 V was found between the lowest and highest sAF quartiles, and the mean VPT was low (approximately 11 V) 4 years after the measurement of sAF, which corresponds to a moderately impaired VPT [24, 25] . Despite this moderately high VPT value, the highest sAF quartile was independently associated with increased VPT. High sAF has already been reported in patients with foot ulcers, the main morbidity of DPN [27, 28] . Our results show that even before reaching a VPT that reflects a severe lesion of a large nerve fibre or a high risk of foot ulcer, sAF reflects the worsening of large fibre function.
Pain can be among the first symptoms of DPN involving the intra-epidermal nerve fibre, unmyelinated fibre and small fibre function [2] . An experimental study showed that some AGE (Methylglyoxal) are implicated in the mechanism of hyperalgesia by increasing the electrical excitability of sensory neurons and slowing the nerve conduction [29] . The current study strengthens this result by suggesting that even before reaching the score threshold of ≥4 for the diagnosis of neuropathic pain, a higher tissue AGE as reflected by the sAF precedes a complaint related to pain.
Muscle weakness is a late complication of DPN with motor nerve involvement; however, the latter is unusual in DPN, especially in the upper limbs [2] . In addition to motor nerve function, sensory or autonomic nerve function could contribute to a loss of muscle strength [30] . However, mechanisms other than nerve lesion can also contribute to muscle weakness. The age-related accumulation of AGE in skeletal muscle, accelerated by diabetes, could also directly contribute to lower muscle strength [31] . sAF has been associated with muscle strength in elderly men or women [32, 33] . Our results show that in a sample of middle-aged individuals with type 1 diabetes, an increase in the sAF is also associated with the loss of upper limb strength in women. This gender-specific effect could be explained by the fact that, in addition to the upper limb strength being lower compared with that of men, in this sample, the age of the women corresponded to the peri-menopausal period; in the process of organic change during this period, muscle strength could be more sensitive to factors such as the accumulation of AGE [34] .
Lesions of small fibres that innervate sweat glands have been shown to develop early in patients with DPN even when large myelinated fibre function is still normal [35] . The Sudoscan device provides quantitative measurements of the ESC, which allows an evaluation of the severity of the autonomic disorder [13, 16, 36] . In a previous study of neuropathy in type 1 diabetes, serum AGE (Carboxymethyllysine) were associated with lesions of small fibres that were evaluated by intra-epidermal nerve fibre density measured 10 years later [37] . Consistent with this result, we found that the highest quartile of sAF is associated with a lower ESC despite the normal sudomotor function of our sample with a mean ESC that is superior to the 70-μS threshold [13, 16] . This result shows that in type 1 diabetes, sAF is related to the worsening of ESC at an early time, which reflects early lesions of the small fibres.
Some limitations must be kept in mind. First, neuropathy was not systematically evaluated at inclusion. Our study can therefore not be considered as prospective. To our knowledge, no report has been published about the time course of sAF in patients with type 1 diabetes. The unique longitudinal study from Gerrits et al. included patients with recent type 2 diabetes [38] , and their sAF was stable: baseline value at 2.71 ± 0.69 AU and 2.79 ± 0.77 AU three years later. Fourteen percent of our patients had signs of neuropathy at the 4-year follow-up, which is consistent with the incidence of clinically evident DPN in the Diabetes Control and Complications Trial study (respectively, 11% and 18% in the intensive and conventional treatment groups after an average of 6.5 years of follow-up) [39] . Moreover, a reverse causality appears unlikely because the accumulation of AGE is observed in the peripheral nerves and thought to have an important role in axonal damage and neuronal apoptosis [6] . Another limit is the absence of a nerve conduction study to confirm DPN. However, even if nerve conduction studies demonstrate normal large fibre function, small fibres are affected early in DPN. Therefore, for the diagnosis of subclinical neuropathy, the Toronto Expert panel Group recommends a small-fibre assessment [35] which we performed with the measurement of feet ESC [13] .
To conclude, because DPN is irreversible, early detection at the subclinical stage is important to slow or stabilize the sensory deficit and to provide education for the prevention of foot ulcers. The simple and non-invasive screening of sAF among type 1 diabetic patients could be useful to select patients for early detection of neuropathy. During the last 20 years an important therapeutic advance was made regarding long term diabetic complications, principally cardiovascular morbidity and mortality. We see also a better therapeutic approach to patients with diabetic retinopathy, and there is presently a list of new drugs in phase II and III dedicated to our patients with diabetic nephropathy. Although diabetic peripheral neuropathy is one of the most common complications that lead to great injury, our ability to treat these patients is still very poor. The positive association we find between the accumulation of AGEs and the signs of neuropathy four years later seems important and useful.
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